ライフサイエンスコーパス: plasma cell tumor

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 may not be appropriate for the treatment of plasma cell tumors.

2 le in the development of a broad spectrum of plasma cell tumors.

3 tively or IGF-I-dependently activated in all plasma cell tumors.

4 ned the mechanism of CD23 down-regulation by plasma cell tumors.

5 ose Ig and Myc-family genes in AID-deficient plasma cell tumors.

6 m for the derivation of cytokine-independent plasma cell tumors and suggest that both IL-6-dependent

7 tible to the development of pristane-induced plasma cell tumors, and have a rare allelic variant in t

8 IgM-secreting plasma cell tumors are rare variants of typical isotype-

9 e previously found that splenic B cells from plasma cell tumor-bearing mice exhibit decreased CD23 ex

10 reased CD23 expression on B cells induced by plasma cell tumors because 1) Abs to IL-10 prevent the l

11 to IL-10 prevent the loss of CD23 induced by plasma cell tumors both in vitro and in vivo; 2) enginee

12 repressed class II transactivator gene in a plasma cell tumor but, in several other tumor cell lines

13 6K and Akt may be differentially used by the plasma cell tumors derived from mice and humans, respect

14 Plasma cell tumors display a wide spectrum of clinical p

15 Collectively, these results demonstrate that plasma cell tumors down-regulate CD23 expression on B ce

16 The failure of rapamycin to inhibit plasma cell tumor growth suggests that FRAP antagonists

17 combinations with c-myc in t(12;15)-positive plasma cell tumors in BALB/c mice.

18 tions between Ig switch regions and c-Myc in plasma cell tumors in mice.

19 tion into Igh predictably induces B-cell and plasma-cell tumors in mice, providing a valuable mouse m

20 The development of murine plasma cell tumors induced by raf/myc containing retrovi

21 Plasma cell tumor induction in mice by pristane is under

22 osteolytic lesions were observed adjacent to plasma cell tumor masses in the bone marrow, indicating

23 the setting of a genetic disease, the B-cell/plasma cell tumor microenvironment (TME) contributes sig

24 been eliminated, developed pristane-induced plasma cell tumors over a shorter latency period than th

25 Mouse plasma cell tumor (PCT) and human multiple myeloma (MM)

26 We extracted nascent plasma cell tumor (PCT) cells from within inflammatory o

27 In contrast, mouse plasma cell tumor (PCT) lines, expressing wild type PTEN

28 within the cell, we studied pristane-induced plasma cell tumors (PCTs).

29 Mice susceptible to plasma cell tumors provide a useful model for human mult

30 Murine plasma cell tumors share a number of common features wit

31 pecially broad and high expression levels in plasma cell tumors such as multiple myeloma (MM).

32 In plasma cell tumors such as multiple myeloma the repressi

33 ouble-transgenic Myc/Bcl-X(L) mice developed plasma cell tumors with short onset (135 days on average

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。